CIM
MYGN icon

Contravisory Investment Management’s Myriad Genetics MYGN Stock Holding History

Contravisory Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,371
Closed -$229K – 417
2024
Q3 		$229K Buy
+8,371
New +$227K 0.05% 205
2015
Q1 		– Sell
-175
Closed -$6K – 177
2014
Q4 		$6K Hold
175
– – ﹤0.01% 146
2014
Q3 		$7K Hold
175
– – ﹤0.01% 122
2014
Q2 		$7K Buy
+175
New +$6.51K ﹤0.01% 122

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Contravisory Investment Management's MYGN Position: Q4 2024 in Review

Contravisory Investment Management sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 8,371 shares — an estimated $229K sold.

Contravisory Investment Management first reported a position in MYGN in Q2 2014 and held it in 4 quarters. The position peaked at $229K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Contravisory Investment Management reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Contravisory Investment Management sold 8,371 Myriad Genetics shares in Q4 2024, an estimated $229K.
  • Contravisory Investment Management first reported a position in Myriad Genetics in Q2 2014 and held it in 4 quarters.
  • Contravisory Investment Management's Myriad Genetics position peaked at $229K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Contravisory Investment Management's 13F filing for Q4 2024, filed 14 Jan 2025.